Immunovant, Inc.

Healthcare

NASDAQ:IMVT · NASDAQ Global Select

Market Cap $6.90B Beta 0.79 P/E (TTM) -13.5

$33.62 +2.25%

+$0.74 today

52W Low $14.32High $36.29

Vol 1.14M · Avg 1.85M

EPS (TTM)-$2.48

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+114.69%

Period High

$35.56

Period Low

$14.69

Latest

$33.62

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Kymera Therapeutics, Inc.

NASDAQ:KYMR

$7.09B

Praxis Precision Medicines, Inc.

NASDAQ:PRAX

$5.64B

Akero Therapeutics, Inc.

AKRO

$4.50B

Crinetics Pharmaceuticals, Inc.

NASDAQ:CRNX

$3.63B

ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

$3.61B

NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

$3.55B

Viking Therapeutics, Inc.

NASDAQ:VKTX

$3.34B

Dyne Therapeutics, Inc.

NASDAQ:DYN

$3.01B

Soleno Therapeutics, Inc.

SLNO

$2.76B

Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

$2.40B

What is the latest IMVT filing?

The latest filing shown is 4 dated May 29, 2026.

How many recent filings does IMVT have?

Intrinsic Alpha currently shows 20 recent filings for IMVT.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.